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SCIENTIFIC EDITORIAL
Is the Thoratec® paracorporeal ventricular assist
device a primary or secondary device to support
patients with refractory cardiogenic shock?
L’assistance ventriculaire paracorporelle par Thoratec® est-elle indiquée en
première ou en seconde intention chez les patients en choc cardiogénique
réfractaire ?
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Temporary mechanical circulatory support should be considered for rescuing patients with
refractory cardiogenic shock [1]. This technique has been used successfully as a bridge
to myocardial recovery or cardiac transplantation in patients with various aetiologies of
overt cardiac failure, e.g., acute myocardial infarction, end-stage dilated cardiomyopa-
thy, viral or toxic myocarditis, complications of cardiac surgery and cardiac arrest [2—4].
The Thoratec® paracorporeal ventricular assist device (Thoratec® PVAD) can be used inSurvival;
Extracorporeal
membrane
oxygenation
these indications. It is a pulsatile-ﬂow, univentricular or biventricular cardiac assist device
(BiVAD).
In this issue of Archives of Cardiovascular Diseases, Kirsch et al. [5] present their
single-centre experience between January 1996 and June 2008, in a retrospective study
Abbreviations: BiVAD, Biventricular assist device; PVAD, Paracorporeal biventricular assist device; ECMO, Extracorporeal membrane
oxygenation.
 Single-centre experience with the Thoratec® paracorporeal ventricular assist device for patients with primary cardiac failure,
Kirsch M., Vermes E., Damy T., Nakashima K., Sénéchal M., Boval B., Drouet L., Loisance D., doi:10.1016/j.acvd.2009.03.010.
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ssessing the outcomes of 84 patients with cardiogenic shock
upported primarily by a Thoratec® PVAD. The reasons for
sing a ventricular assist device (VAD) were similar to those
eported in other recent single- and multicentre studies
6—9], except for the exclusion of patients with postcar-
iotomy shock. In line with the literature, the initial gravity
f this population was high, reﬂected by a low mean car-
iac index before VAD implantation, the high percentage
f patients on inotropic drugs and the high blood concen-
rations of creatinine, liver enzymes and total bilirubin at
he time of Thoratec® PVAD implantation. Sixty-two (74%)
atients received biventricular support, 20 (24%) received
solated left ventricular support and two (2%) received iso-
ated right ventricular (RV) support (indications for BiVAD
ere at the discretion of the surgeon). The median duration
f support was 42 (2.3 to 268). While the rates of adverse
vents were high, they were similar to those reported in
ther studies [10,11], and included surgical re-exploration
ue to bleeding or cardiac tamponade (36%), VAD can-
ulae infection (21%) and neurological infections (30%).
our patients with a left ventricular assist device (LVAD)
resented RV dysfunction, reﬂecting the difﬁculties in eval-
ating RV function. Thirty-six (43%) patients died during
echanical assist device support. Forty-seven (56%) patients
ere bridged successfully to transplantation (n = 42, 50%) or
ecovery (n = 5, 6%). Actuarial survival estimates after trans-
lantation were 78.7± 6.3% at 1 year and 62.6± 8.3% at
years. Survival to transplantation or recovery and actuarial
urvival estimates after transplantation were not statisti-
ally signiﬁcantly different in LVAD and BiVAD patients.
Thus, the authors concluded that Thoratec® PVAD should
e used as the primary device to support patients with
efractory cardiogenic shock. Nevertheless, this approach
nvolves a surgically aggressive procedure in critically ill
atients and it cannot be implanted in all hospital centres.
hort-term assist devices, such as venoarterial extracor-
oreal membrane oxygenation (ECMO), have proved as
fﬁcient as BiVAD [2,3,12]. They are less invasive, eas-
er to implant and more cost-effective. ECMO provides
temporary, venoarterial, continuous-ﬂow extracorporeal
irculation that can support the left and right ventricles.
cannula implanted into the right atrium drains venous
lood, which is reinjected into the aorta after oxygena-
ion. Thus the heart is unloaded and the haemodynamic
tatus is restored by a pump ﬂow that can reach 8 L/min
n central ECMO. It can be implanted by experienced sur-
eons working across hospital sites, allowing the transfer
f unstable patients to specialist cardiac surgery centres13]. Kirsch et al. [5] state that ECMO is a continuous
ump and provides incomplete left ventricular unload-
ng.
Experimental studies have reported alterations in
icrovascular perfusion induced by continuous-ﬂow VAD and
lower efﬁciency of continuous perfusion VAD compared
ith pulsatile perfusion VAD in the recovery of renal, hepatic
nd metabolic function [14,15]. However, most recent clin-
cal studies report that continuous-ﬂow VAD is as effective
s pulsatile-ﬂow VAD on left ventricular unloading, cardiac
aemodynamics and end-organ function recovery [16—18].
oreover, left ventricular unloading can be improved by a
ischarge in the pulmonary artery, averting some pulmonary
edema. ECMO also supports both the left and right ven-
ricles, avoiding right ventricular dysfunction, which can
ppear with left VAD. The implantation of BiVAD increases
he duration of surgery in critically ill patients. The assess-
ent of right ventricular function remains difﬁcult. Some
uthors have tried to identify LVAD-assisted patients who
ould go on to develop RV dysfunction, proposing clinical
isk factors and biological scores [19,20], but no index cur-
ently exists in the literature that can evaluate RV function
recisely.
While the beneﬁts and efﬁcacy of Thoratec® PVAD have
een clearly demonstrated in the study by Kirsch et al., as
ell as in many other studies [1,5—9], a short-assist device
uch as ECMO should be considered as the ﬁrst-line approach
n patients with refractory cardiogenic shock and could be
ridged by more invasive VAD such as Thoratec® PVAD in
he case of incomplete left ventricular unloading or as ﬁnal
herapy.
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